Status:
RECRUITING
Periodic Fasting for Treatment of Long Covid in Adults: a Pilot Study
Lead Sponsor:
University of Luxembourg
Conditions:
Long Covid
Chronic Inflammation
Eligibility:
All Genders
18-64 years
Phase:
NA
Brief Summary
Background: Long COVID, characterized by persistent symptoms following acute COVID-19 infection, has emerged as a significant public health concern. Symptoms range from fatigue, cognitive impairments...
Detailed Description
Background Long COVID syndrome (LCS) is a heterogeneous clinical condition that develops after acute SARS-CoV-2 infection, affecting at least 10% of patients. LCS is characterized by persistent sympto...
Eligibility Criteria
Inclusion
- Age 18-64
- Diagnosis Long Covid Syndrome (post-acute COVID-19 symptoms persisting ≥12 weeks)
- Normal body Mass Index (18.5 to 25 kg/m2)
- Marginal Iron status ( PF\< 25 ng/ml)
- Able to communicate in and comprehend English and/or German and/or French language
- Present written / signed declaration of consent
- Ability to understand the patient information and willingness to sign the consent form
- Consent to specimen collection and specimen use
Exclusion
- Current underweight condition (body mass index less than 18.5 kg/m2) or weight loss exceeding 3 kg within the last month or 5 kg within the last three months.
- Existing / current eating disorder within the past five years (e.g., anorexia, bulimia).
- Psychiatric condition that limits understanding of the examination protocol (unable to consent)
- Severe internal disease (e.g. kidney deficiency with creatinine \> 2mg/dl), chronic inflammatory illness other than LCS
- Participation in another intervention study.
- Existing vegan diet or fasting during the last six months
- Pregnancy or breastfeeding status.
- Presence or suspicion of pre-existing ME/CFS or early autonomous dysfunction
- Diagnosis of chronic inflammatory bowel diseases, celiac disease or colorectal cancer according to the guidelines of the German Society of Gastroenterology
- Use of anti-psychotic drugs
- Antibiotic use during the previous 12 months
- Start of novel drug therapy
- Contraindication for additional blood draws (e.g. hemoglobin \<10)
Key Trial Info
Start Date :
February 19 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2025
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06522750
Start Date
February 19 2025
End Date
September 30 2025
Last Update
March 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rehaklinik CHNP
Ettelbruck, Luxembourg, L-9012